卡博替尼联合纳武利尤单抗治疗非透明细胞肾细胞癌患者:一项2期试验的更新结果
这项2期试验更新分析了卡博替尼联合纳武利尤单抗治疗转移性非透明细胞肾细胞癌(nccRCC)的疗效与安全性,40例患者接受标准剂量治疗。中位随访34个月时,客观缓解率(ORR)为48%(95%CI 31.5-63.9%),中位无进展生存期(PFS)13个月(95%CI 7-16),中位总生存期(OS)28个月(95%CI 23-43)。未观察到新的安全性信号。
要点
- 卡博替尼联合纳武利尤单抗在转移性nccRCC中ORR达48%(95%CI 31.5-63.9%)。
- 中位PFS为13个月(95%CI 7-16),中位OS为28个月(95%CI 23-43)。
- 联合方案未观察到新的安全性信号。
核心结论
- 延长随访分析显示卡博替尼联合纳武利尤单抗在转移性nccRCC中具有前景的疗效,并提示可持续缓解。
研究设计与样本
- 2期试验,纳入40例转移性nccRCC患者,接受卡博替尼联合纳武利尤单抗标准剂量治疗。
主要发现
- 中位随访34个月时,ORR为48%(95%CI 31.5-63.9%)。
- 中位PFS为13个月(95%CI 7-16);12个月和24个月PFS率分别为51%(95%CI 34-65%)和23%(95%CI 11-37%)。
- 中位OS为28个月(95%CI 23-43);18个月和36个月OS率分别为70%(95%CI 53-82%)和44%(95%CI 28-60%)。
- 卡博替尼联合纳武利尤单抗未观察到新的安全性信号。
关键数值与推荐
- 主要终点为根据实体瘤疗效评价标准v1.1的ORR。
- 次要终点包括PFS、OS和不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment options are limited for patients with non-clear cell renal cell carcinoma (nccRCC). Patients with nccRCC experienced a favorable objective response rate (ORR) in a phase 2 trial of cabozantinib plus nivolumab. We now report updated efficacy and safety results at median follow-up of 34 mo for patients with papillary, unclassified, or translocation-associated RCC. Cabozantinib and nivolumab were administered at standard doses to patients with metastatic nccRCC that had progressed on zero or one line of systemic therapy. The primary endpoint was the ORR according to Response Evaluation Criteria in Solid Tumors v1.1. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and adverse events. Forty patients were treated. At median follow-up of 34 mo for survivors, the ORR was 48% (95% confidence interval [CI] 31.5-63.9%). Median PFS was 13 mo (95% CI 7-16); the 12-mo and 24-mo PFS rates were 51% (95% CI 34-65%) and 23% (95% CI 11-37%), respectively. Median OS was 28 mo (95% CI 23-43); the 18-mo and 36-mo OS rates were 70% (95% CI 53-82%) and 44% (95% CI 28-60%), respectively. No new safety signals were seen with cabozantinib and nivolumab. This extended follow-up analysis demonstrates promising efficacy, and highlights the potential for sustained responses with cabozantinib plus nivolumab in patients with metastatic nccRCC.
引用
- Fitzgerald KN, Lee CH, Voss MH, et al. Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial. Eur Urol. 2024. PMID: 38782695. doi:10.1016/j.eururo.2024.04.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。